Archive for the ‘Adult Stem Cells’ Category

5 Benefits to Using Adult Stem Cells in Cancer Research

Adult Stem Cells | Posted by admin
Jul 05 2018

While much of the popular media attention over the last 10 years has focused on embryonic stem cells, in fact, the adult stem cell has been shown to be a viable and valuable source in the long fight to better understand cancer’s origins and treatment possibilities. Adult stem cells, in brief, are also known as progenitor cells or somatic stem cells. They are found in minute quantities in nearly every human body organ and tissue. Their key function is maintenance and repair of their specific tissues.

1. Adult stem cells carry no ethical concerns.

We’ve all followed the loud controversy over the use of embryonic stem cell lines for research, and the ethical questions that surround their harvesting from a days-old human embryo. Adult stem cells avoid this ethical dilemma entirely. They can be isolated from a variety of tissue sources, including adult bone marrow, bone marrow mononuclear cells (BMMCs), peripheral blood mononuclear cells (PBMCs), umbilical cord blood, fresh tissue, and tumor-derived tissue cells.

2. Adult stem cells are unspecialized.

The adult stem cell is an unspecialized cell that is capable of long-term renewal, via cell division over long time periods. These stem cells can also give rise to different cell types, making their utility high for researchers studying the many types of human cancers.

3. Adult stem cells can regenerate malignant cells.

Important cancer research often focuses on the stem cells that can be isolated from a malignant cancerous tumor. Cancer researchers are pursuing the idea that the reason for the failure of current cancer treatments may be due to the fact that such treatments don’t destroy the cancer stem cells. While cancer stem cells total just one to three percent of all tumor cells, these cells are the only ones that can cause regeneration of malignant cells, thus inducing cancer cells to grow.

Researchers at the University of Michigan are actively pursuing this theory for developing better treatments for breast cancer. One key finding utilizing adult stem cells, say UM scientists, is the fact that, “mutations in genes called HER2 and PTEN triggered rapid cell division and self-renewal in breast cancer stem cells. This caused the stem cells to develop abnormally and invade surrounding breast tissue. When the scientists treated the cells with drugs known to inhibit activity of these genes, the number of cancer stem cells dropped dramatically.”

4. Lower rejection rates.

Researchers have long observed that adult stem cells used in noted that adult stem cells dont present with the same level of immunological rejection challenges as do embryonic stem cells because they are harvested from the same patient, leading to a lower rejection rate. For example, adult stem cells have been used for many years to treat certain cancers via a bone marrow transplant.

5. Comparing adult and pediatric cancers.

Wilms’ Tumor is a common pediatric renal cancer. Cancer researchers in this study set out to compare and contrast the differences in tumor biology that are known to exist between adult and pediatric cancers. They found that there are cancer stem cells in pediatric WTs and believe that these could help in developing targeted cancer therapies for pediatric solid tumors.

May we source high-quality adult stem cells for your cancer research program?

See the original post here:
5 Benefits to Using Adult Stem Cells in Cancer Research

Sources of Adult Stem Cells – Stem Cell Institute

Adult Stem Cells | Posted by admin
Jul 05 2018

*Unlike bone marrow and cord blood, Human umbilical cord tissue is a rich source of mesenchymal stem cells. Umbilical cord tissue-derived cells are best suited for tissue regeneration due to the tissue repairing function of the mesenchymal stem cells. They are also well-suited for immune system modulation and reducing inflammation.

Bone marrow is a good source of CD34+ stem cells (but a poor source of mesenchymal stem cells) bone marrow-derived stem cells provide support for tissue regeneration via revascularization properties and their ability to support mesenchymal stem cells in the body.

Because we have three major adult stem cells sources at our disposal, including the ability to expand cells into larger numbers when indicated, we can select optimal stem cell combinations for each disease and, if necessary, each individual we treat.

Like bone marrow, cord blood is source of CD34+ stem cells (but a poor source of mesenchymal stem cells). These stem cells provide support for tissue regeneration via revascularization properties and their ability to support mesenchymal stem cells in the body.

Most protocols using cord blood require Human leukocyte antigen (HLA) typing to match the recipient and donor.

We do not use cord blood-derived stem cells at Stem Cell Institute.

Adipose tissue is a rich source of mesenchymal stem cells (MSCs) and T-regulatory cells which modulate the immune system. Adipose-derived cells can be used for treating systemic autoimmune and inflammatory conditions. They also play a role in regenerating injured tissue.

Because we have found that the immune modulatory and anti-inflammatory properties of umbilical cord tissue-derived mesenchymal stem cells (HUCT-MSCs) are superior to those harvested from fat, we no longer employ fat-derived MSCs in our treatment protocols.

*All donated cords are the by-products of normal, healthy births. Each cord is carefully screened for sterility and infectious diseases under International Blood Bank standards.

Original post:
Sources of Adult Stem Cells – Stem Cell Institute

Adult Stem Cell Therapy 101, MSCTC

Adult Stem Cells | Posted by admin
Jul 05 2018

The initial concept of regenerative medicine dates all the way back to 330 BC, when Aristotle observed that a lizard could grow back the lost tip of its tail. Slowly over time, humans have grown to understand regenerative medicine, and how it may change the way we treat diseases. It’s been only relatively recently that adult (non-embryonic) stem cell therapy, a type of regenerative medicine, has gathered fast momentum. The below video illustrates key (not all) highlights in how stem cell therapy research has progressed over the last several decades.

Adult (non-embryonic) stem cells are unspecialized or undifferentiated cells,which means they have yet to develop into a specific cell type. Found in most adult tissues, adult stem cells have two primary properties:

Simply put, adult stem cells have the potential to grow into any of the body’s more than 200 cell types.

Adult stem cells have been found in most parts of the body, including brain, bone marrow, blood vessels, skin, teeth and heart. There are typically a small number of stem cells in each tissue. Due to their small number and rate of division (growth), it is difficult to grow adult stem cells in large numbers. Scientists at the Midwest Stem Cell Therapy Center are working to understand how to grow large amounts of adult stem cells in cell culture. These scientists are also working with more “primitive” stem cells, isolated from the umbilical cord after normal births.

These stem cells are in much higher abundance than in adult tissues, can be differentiated into several different cell types, and their capacity to divide is much faster, making them good candidates for applications in treating injury or disease. An example of this is the use of these cells in treating Graft vs. Host Disease (GvHD), a condition which affects approximately 40-50% of patients receiving allogeneic transplants (i.e., transplant from another person) for blood cancers by taking advantage of a key immunosuppressive characteristic the cells possess.

The practice of stem cell therapy is nothing new: One of the oldest forms of it is the bone marrow transplant, which has been actively practiced since the late 1960s. Since then, scientists haven’t slowed downwith the advancement of adult stem cell therapy. Every day, scientists worldwide are researching new ways we can harness stem cells to develop effective new treatments for a host of diseases. In the case of a patient suffering with a blood cancer such as leukemia, a bone marrow transplant will replace their unhealthy blood cells with healthy ones. This same concept – inserting healthy cells so they may multiply and form new tissue or repair diseased tissue – can be applied to other forms of stem cell therapy.

Stem cell research continues to advance as scientists learn how an organism develops from a single cell and how healthy cells replace damaged cells. For example, the Midwest Stem Cell Therapy Center is collaborating to investigate the potential of a select group of umbilical cord stem cells in the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gerhig’s disease). Developing a stem cell treatment that has been shown to be both safe and efficacious is not as simple as removing stem cells from one part of the body and putting it in another.

Working with appropriate regulatory agencies, the Midwest Stem Cell therapy Center is conducting R&D activities that will permit the Center to conduct human clinical trials on a variety of diseases over the next several years. This process – similar to the development of a new drug – will, when completed, assure patients in both clinical trials and eventually patients using the approved product, that the product is safe for use in humans and the stem cells being administered are effective in treating the injury or disease they are being used for.

When considering a cell therapy treatment, it is important to understand how your treatment will be administered and ensure that the provider is well-qualified. Stem cell clinics have popped up around the world, touting 100% success, however, in many cases these experimental treatments have yet to be evaluated by the FDA (Food & Drug Administration) or other regulatory agencies in their countries of origin. Reputable centers, including the MSCTC, are working with the FDA to develop regulations that protect the health of the patient and hold providers to high standards of treatment. Without these regulations in place, unqualified providers may endanger patients’ health. For example, as in organ transplants, patients that receive stem cell therapy are at risk of their immune system rejecting the transplant. To avoid this, immune system-suppressing drugs must be taken. Further, if stem cells are not manipulated correctly, the receiving patient can be exposed to bacteria, fungi or viruses which have been picked up during the manipulations of the stem cells, or, in some cases, receive cells that are not appropriate for use in treating a specific injury or disease.

Last modified: Mar 21, 2016

The rest is here:
Adult Stem Cell Therapy 101, MSCTC

What are Adult Stem Cells? | Adult Stem Cell Treatment

Adult Stem Cells | Posted by admin
Jul 02 2018

The primary role of adult stem cells in humans is to maintain and repair the tissue in which they are found. While we call them adult stem cells, they are more accurately called somatic (from the Greek word soma = body) because they come virtually any body tissue, not only in adults but children and babies as well.

Stem cells are very flexible cells, sometimes considered immature, that have not developed to a final specialized cell type (like skin, liver, heart, etc.) Since they have not yet specialized, stem cells can respond to different signals and needs in the body by becoming any of the various cell types needed, e.g., after an injury to repair an organ. In that sense they are a bit like a maintenance crew that keeps repairing and replacing damaged or worn out cells in the body.

A stem cell is essentially a blank cell, capable of becoming another more differentiated cell type in the body, such as a skin cell, a muscle cell, or a nerve cell. Microscopic in size, stem cells are big news in medical and science circles because they can be used to replace or even heal damaged tissues and cells in the body. They can serve as a built-in repair system for the human body, replenishing other cells as long as a person is still alive.

Adult stem cells are a natural solution. They naturally exist in our bodies, and they provide a natural repair mechanism for many tissues of our bodies. They belong in the microenvironment of an adult body, while embryonic stem cells belong in the microenvironment of the early embryo, not in an adult body, where they tend to cause tumors and immune system reactions.

Most importantly,adult stem cells have already been successfully used in human therapies for many years.As of this moment,no therapies in humans have ever been successfully carried out using embryonic stem cells.New therapies using adult type stem cells, on the other hand, are being developed all the time.

Stem Cells are being used today to help people suffering from dozens of diseases and conditions. This list reveals the wide range of applications that adult stem cells are having right now:

Cancers:

Auto-Immune Diseases

Cardiovascular

Ocular

Neural Degenerative Diseases and Injuries

Anemias and Other Blood Conditions

Wounds and Injuries

Other Metabolic Disorders

Liver Disease

The primary reason would be the ethics, since getting embryonic stem cells requires destruction of a young human embryo. The other, practical reasons are that people feel money spent on embryonic stem cell research could be better spent on other stem cell research.

The biggest misconception people have about stem cell research is that it is only embryonic that are useful. In fact, other stem cell types are proving to be much more useful. The best stem cells for patients are Adult Stem Cells; these are taken from the body (e.g., bone marrow, muscle, even fat tissue) or umbilical cord blood and can be used to treat dozens of diseases and conditions. Over 1 million people have already been treated with adult stem cells. (versus no proven success with embryonic stem cells.)https://lozierinstitute.org/fact-sheet-adult-stem-cell-research-transplants/Yet most people dont know about adult stem cells and their practical success.

Another type of stem cell that is proving very useful is induced pluripotent stem cells (iPS cells.) These can be made from any cell, such as skin, and from any person. They act like embryonic stem cells, but are made from ordinary cells and so dont require embryo destruction, making them an ethical source for that type of cell. They have already been used to create lab models of different diseases.

See the original post here:
What are Adult Stem Cells? | Adult Stem Cell Treatment

Your Stem Cell Questions Answered – webmd.com

Adult Stem Cells | Posted by admin
Oct 13 2017

There’s a lot of fiction surrounding stem-cell facts. To separate one from the other, WebMD has consulted experts including Mahendra Rao, MD, PhD, director of the Center for Regenerative Medicine at the National Institutes of Health; Todd McDevitt, PhD, director of the Stem Cell Engineering Center at Georgia Tech; Mary Laughlin, MD, past president of the International Society for Cellular Therapy; and Joshua Hare, MD, director of the Interdisciplinary Stem Cell Institute at the University of Miami.

Here are the questions they answered:

A: The term “stem cells” includes many different kinds of cells.

What they have in common is that they have the ability to make other types of cells. No other cell in the body can do that.

Some stem cells can renew themselves and become virtually any cell in the body. Those are called pluripotent stem cells. They include embryonic stem cells.

Other stem cells don’t have as much potential for self-renewal and can’t make as many types of cells.

The most basic kind of stem cells are the cells that make up an embryo soon after an egg is fertilized. These stem cells divide over and over, eventually making almost all the different cells in the body.

Adult stem cells, in contrast, are “fully differentiated.” That means they are what they are and do what they do. They can’t choose another career.

In many organs, however, adult stem cells linger throughout life. They are part of the body’s internal repair system. Researchers are still working to discover what adult stem cells from various parts of the body can and can’t do. Normally, these relatively rare cells act only on the organ or tissue type in which they are found.

Recently, researchers have learned to reprogram adult cells to become pluripotent cells. These cells, called induced pluripotent cells or iPSCs, have many of the same properties as embryonic stem cells. It’s not yet clear whether these cells might carry subtle DNA damage that limits their usefulness.

A: Early in development, a fertilized egg becomes an embryo. The embryo is made up of stem cells that divide over and over again, until these stem cells develop into the cells and tissues that become a fetus.

During in-vitro fertilization, eggs taken from a woman’s body are fertilized with sperm cells. If not implanted in a woman’s womb, these embryos are discarded.

Researchers have learned to take embryonic stem cells from unused in-vitro fertilizations and, in laboratory culture, to get them to make more embryonic stem cells. Embryonic stem cells are not taken from fertilized eggs or embryos that have been in a woman’s womb.

While embryonic stem cells can become any kind of cell in the body, it’s unlikely they would be used directly as treatments. Because they have the ability to divide over and over again, they can become rapidly growing tumors. And because they are in such an early stage of development, they take a long time to become functional adult cells.

However, researchers are learning to coax embryonic stem cells to become more mature stem cells. One clinical trial, for example, matures embryonic stem cells into nerve stem cells. These nerve stem cells are being explored as a treatment for Lou Gehrig’s disease.

A: Adult stem cells have some advantages. When they come from your own body, your immune system will probably not try to reject them. And adult stem cells aren’t controversial.

But there are several main disadvantages to using adult stem cells:

A: A relatively small number of stem cells taken from the body can be grown in the laboratory until they have created millions and millions of new stem cells. This makes it possible for researchers to explore cell-based therapies.

Cell-based therapies, collectively known as regenerative medicine, hold the promise of repairing or even replacing damaged or diseased organs.

Depending on which tissues they come from, stem cells have very different properties. Those from umbilical cord blood are quite different from those from fat, for example.

A: Yes. Stem cells from bone marrow have long been used to treat certain types of leukemia.

The bone marrow is a rich source of blood stem cells. These cells replace the white blood cells crucial to the immune system.

When used for leukemia, the goal is to to wipe out all of a person’s white blood cells with radiation and/or chemotherapy — and then to replace them with a bone marrow transplant from a matched donor. Stem cells from the donor marrow replace the diseased blood cells with healthy blood cells.

A stem cell product designed to avoid the need for a matched donor recently received limited approval in Canada. The product, Prochymal, appears to rescue bone marrow transplant patients who are rejecting their transplant.

In the U.S., the FDA has approved a product called Hemacord, which contains blood stem cells derived from cord blood. The product is approved for patients with diseases that affect their ability to make new blood cells, such as certain blood cancers and immune disorders.

A: That remains to be seen. Potential dangers include:

There is also risk in some of the procedures used to get stem cells out of the body (such as from liposuction or spinal tap) or to deliver stem cells to the body (such as implanting them in the heart, brain, spinal cord, or other organs). That’s not so much about the stem cells, but because of the procedures themselves.

Researchers are studying all of that. Without carefully controlled clinical trials, there’s no way to know what might happen in the long term, or even in the short term. That’s why the FDA discourages the use of stem cells except in clinical trials or approved therapies.

If you are thinking about pursuing stem cell therapy, talk to your doctor first. In the U.S. and abroad, many clinics offer unproven stem cell treatments that have never been tested for safety or effectiveness.

SOURCES:

Mahendra Rao, MD, PhD, director, Center for Regenerative Medicine, National Institutes of Health, Bethesda, Md.

Todd McDevitt, PhD, director, Stem Cell Engineering Center, Georgia Institute of Technology, Atlanta.

Mary Laughlin, MD, past president of the International Society for Cellular Therapy.

Joshua Hare, MD, director, Interdisciplinary Stem Cell Institute, University of Miami.

National Institutes of Health web site.

FDA web site.

More here:
Your Stem Cell Questions Answered – webmd.com

Adult Stem Cell Therapy in Cancer, MSCTC – KUMC

Adult Stem Cells | Posted by admin
Oct 13 2017

HUMAN STUDIES

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, Elter T, von Bubnoff N, Dreyling M, Ringhoffer M, Krause SW, Derigs G, Klimm B, Niemann D, Fritsch K, Finke J, Illerhaus G. Haematologica. 2013 May;98(5):765-70. doi: 10.3324/haematol.2012.076075. Epub 2013 Jan 8. FREE ARTICLE

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Lancet Oncol. 2013 Sep;14(10):999-1008. doi: 10.1016/S1470-2045(13)70309-7. Epub 2013 Jul 25. FREE ARTICLE

A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1. Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. Bone Marrow Transplant. 2013 Jul;48(7):947-52. doi: 10.1038/bmt.2012.276. Epub 2013 Jan 21. FREE ARTICLE

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Korfel A, Elter T, Thiel E, Hnel M, Mhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Rth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L. Haematologica. 2013 Mar;98(3):364-70. doi: 10.3324/haematol.2012.077917. Epub 2012 Dec 14. FREE ARTICLE

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuo MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS. Cancer ImmunolImmunother. 2013 Jan;62(1):125-35. doi: 10.1007/s00262-012-1319-0. Epub 2012 Jul 31. FREE ARTICLE

Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer. VanderWalde A, Ye W, Frankel P, Asuncion D, Leong L, Luu T, Morgan R, Twardowski P, Koczywas M, Pezner R, Paz IB, Margolin K, Wong J, Doroshow JH, Forman S, Shibata S, Somlo G. Biol Blood Marrow Transplant. 2012 Aug;18(8):1273-80. doi: 10.1016/j.bbmt.2012.01.021. Epub 2012 Feb 2. FREE ARTICLE

Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Grupp SA, Prak EL, Boyer J, McDonald KR, Shusterman S, Thompson E, Callahan C, Jawad AF, Levine BL, June CH, Sullivan KE. Clin Cancer Res. 2012 Dec 15;18(24):6732-41. doi: 10.1158/1078-0432.CCR-12-1432. Epub 2012 Oct 23. FREE ARTICLE

IFN–secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway. Yang X, Du J, Xu X, Xu C, Song W. J Immunol Res. 2014;2014:318098. doi: 10.1155/2014/318098. Epub 2014 May 26. FREE ARTICLE

Combinatorial control of transgene expression by hypoxia-responsive promoter and microrna regulation for neural stem cell-based cancer therapy. Luo Y, Zhu D. Biomed Res Int. 2014;2014:751397. doi: 10.1155/2014/751397. Epub 2014 Apr 17. FREE ARTICLE

Effect of NK4 transduction in bone marrow-derived mesenchymal stem cells on biological characteristics of pancreatic cancercells. Sun YP, Zhang BL, Duan JW, Wu HH, Wang BQ, Yu ZP, Yang WJ, Shan YF, Zhou MT, Zhang QY. Int J Mol Sci. 2014 Mar 3;15(3):3729-45. doi: 10.3390/ijms15033729. FREE ARTICLE

Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice. Zhang Y, Wang J, Ren M, Li M, Chen D, Chen J, Shi F, Wang X, Dou J. J Ovarian Res. 2014 Jan 20;7(1):8. doi: 10.1186/1757-2215-7-8. FREE ARTICLE

Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Metz MZ, Gutova M, Lacey SF, Abramyants Y, Vo T, Gilchrist M, Tirughana R, Ghoda LY, Barish ME, Brown CE, Najbauer J, Potter PM, Portnow J, Synold TW, Aboody KS. Stem CellsTransl Med. 2013 Dec;2(12):983-92. doi: 10.5966/sctm.2012-0177. Epub 2013 Oct 28. FREE ARTICLE

Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. J Transl Med. 2013 Jan 24;11:20. doi: 10.1186/1479-5876-11-20. FREE ARTICLE

Mesenchymal stem cells derived from adipose tissue vs bone marrow: in vitro comparison of their tropism towards gliomas. Pendleton C, Li Q, Chesler DA, Yuan K, Guerrero-Cazares H, Quinones-Hinojosa A. PLoS One. 2013;8(3):e58198. doi: 10.1371/journal.pone.0058198. Epub 2013 Mar 12. FREE ARTICLE

Suppression of peritoneal tumorigenesis by placenta-derived mesenchymal stem cells expressing endostatin on colorectal cancer. Zhang D, Zheng L, Shi H, Chen X, Wan Y, Zhang H, Li M, Lu L, Luo S, Yin T, Lin H, He S, Luo Y, Yang L. Int J Med Sci. 2014 Jun 13;11(9):870-9. doi: 10.7150/ijms.8758. eCollection 2014. FREE ARTICLE

Conditioned media from human adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells efficiently induced the apoptosis and differentiation in human glioma cell lines in vitro. Yang C, Lei D, Ouyang W, Ren J, Li H, Hu J, Huang S. Biomed Res Int. 2014;2014:109389. doi: 10.1155/2014/109389. Epub 2014 May 27. FREE ARTICLE

Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene (PTEN): an imaging demonstration. Yang ZS, Tang XJ, Guo XR, Zou DD, Sun XY, Feng JB, Luo J, Dai LJ, Warnock GL. Onco Targets Ther. 2014 Mar 17;7:441-6. doi: 10.2147/OTT.S59227. eCollection 2014. FREE ARTICLE

Umbilical cord tissue-derived mesenchymal stem cells induce apoptosis in PC-3 prostate cancer cells through activation of JNK and downregulation of PI3K/AKT signaling. Han I, Yun M, Kim EO, Kim B, Jung MH, Kim SH. Stem Cell Res Ther. 2014 Apr 16;5(2):54. [Epub ahead of print] FREE ARTICLE

Stem cells’ guided gene therapy of cancer: New frontier in personalized and targeted therapy. Mavroudi M, Zarogoulidis P, Porpodis K, Kioumis I, Lampaki S, Yarmus L, Malecki R, Zarogoulidis K, Malecki M. J Cancer Res Ther (Manch). 2014;2(1):22-33. FREE ARTICLE

Clinical significance of epithelial-mesenchymal transition. Steinestel K, Eder S, Schrader AJ, Steinestel J. ClinTransl Med. 2014 Jul 2;3:17. doi: 10.1186/2001-1326-3-17. eCollection 2014. Review FREE ARTICLE

Role of BMSCs in liver regeneration and metastasis after hepatectomy. Hang HL, Xia Q. World J Gastroenterol. 2014 Jan 7;20(1):126-32. doi: 10.3748/wjg.v20.i1.126. Review. FREE ARTICLE

NKT cells as an ideal anti-tumor immunotherapeutic. Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, Taniguchi M. Front Immunol. 2013 Dec 2;4:409. doi: 10.3389/fimmu.2013.00409. Review. FREE ARTICLE

Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Brennen WN, Denmeade SR, Isaacs JT. EndocrRelatCancer. 2013 Aug 23;20(5):R269-90. doi: 10.1530/ERC-13-0151. Print 2013 Oct. Review FREE ARTICLE

Mesenchymal stem cells as vectors for lung cancer therapy. Kolluri KK, Laurent GJ, Janes SM. Respiration. 2013;85(6):443-51. doi: 10.1159/000351284. Epub 2013 May 23. Review. FREE ARTICLE

Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review). Yi BR, Choi KJ, Kim SU, Choi KC. Int J Oncol. 2012 Sep;41(3):798-804. doi: 10.3892/ijo.2012.1523. Epub 2012 Jun 20. Review. FREE ARTICLE

Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer. Bao Q, Zhao Y, Niess H, Conrad C, Schwarz B, Jauch KW, Huss R, Nelson PJ, Bruns CJ. Stem Cells Dev. 2012 Sep 1;21(13):2355-63. doi: 10.1089/scd.2012.0060. Epub 2012 Jun 26. Review FREE ARTICLE

The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Ahmed AU, Alexiades NG, Lesniak MS. CurrOpinMolTher. 2010 Oct;12(5):546-52. Review. FREE ARTICLE

Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Bexell D, Scheding S, Bengzon J. MolTher. 2010 Jun;18(6):1067-75. doi: 10.1038/mt.2010.58. Epub 2010 Apr 20. Review. FREE ARTICLE

Stem cells as vectors for antitumour therapy. Loebinger MR, Janes SM. Thorax. 2010 Apr;65(4):362-9. doi: 10.1136/thx.2009.128025. Review. FREE ARTICLE

Crossing the boundaries: stem cells and gene therapy. Ferguson SD, Ahmed AU, Thaci B, Mercer RW, Lesniak MS. Discov Med. 2010 Mar;9(46):192-6. Review. FREE ARTICLE

Directing systemic oncolytic viral delivery to tumors via carrier cells. Nakashima H, Kaur B, Chiocca EA. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):119-26. doi: 10.1016/j.cytogfr.2010.02.004. Epub 2010 Mar 11. Review. FREE ARTICLE

Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Brenner MK, Okur FV. Hematology Am SocHematolEduc Program. 2009:675-81. doi: 10.1182/asheducation-2009.1.675. Review. FREE ARTICLE

Stem cells as delivery vehicles for oncolytic adenoviral virotherapy. Kranzler J, Tyler MA, Sonabend AM, Ulasov IV, Lesniak MS. Curr Gene Ther. 2009 Oct;9(5):389-95. Review. FREE ARTICLE

Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Duan X, Guan H, Cao Y, Kleinerman ES. Cancer. 2009 Jan 1;115(1):13-22. doi: 10.1002/cncr.24013. Review. FREE ARTICLE

Vector-mediated cancer gene therapy: an overview. Seth P. CancerBiolTher. 2005 May;4(5):512-7. Epub 2005 May 5. Review. FREE ARTICLE

Adenovirus as a gene therapy vector for hematopoietic cells. Marini FC 3rd, Yu Q, Wickham T, Kovesdi I, Andreeff M. Cancer Gene Ther. 2000 Jun;7(6):816-25. Review. FREE ARTICLE

Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Clay TM, Custer MC, Spiess PJ, Nishimura MI. PatholOncol Res. 1999;5(1):3-15. Review. FREE ARTICLE

Current status of gene transfer into haemopoietic progenitor cells: application to Langerhans cell histiocytosis. Brenner M. Br J Cancer Suppl. 1994 Sep;23:S56-7. Review. FREE ARTICLE

Last modified: May 22, 2015

Go here to see the original:
Adult Stem Cell Therapy in Cancer, MSCTC – KUMC

How Adult Stem Cells Can Help Stop Pain and Reverse Aging

Adult Stem Cells | Posted by admin
Sep 23 2017

Im so excited to shareone of my latest and greatest biohacking experiments: using stem cells to become younger and stronger. For years, using stem cells for chronic pain, recovery from injury, or even skin tone and texture was thought of as science fiction, a treatment reserved for the ultra-rich, or worse a controversy. Today, these therapies are widely available and have worked wonders for my family and me.

Here youre going to learn about what people are really doing with stem cells, whats real, whats not, and where to go if you want to do it. As you know, I am a guinea pig and professional biohacker, so I like to try things before I recommend them.

Ive had stem cells injected pretty much all over my body in multiple countries so now you dont have to! In fact, Im the second person ever to have stem cells injected into my brain for preventative reasons. (The first was the doctor who did my procedure!)

The human bodys ability to heal on its own is impressive. With a little help from stem cell therapy, it goes from impressive to almost unbelievable. And its not just about healing injuries reversing aging is all about healing and recovering from stress and strain like a young person. Healing is core to resilience. Extracting your own stem cells and then injecting them with intention can upgrade your biology in science fiction-esque ways.

Stem cells can return sight to blind people[1]and hearing to deaf rodents.[2] They repair connective tissue, helping with everything from spinal injury to a torn Achilles tendon.[3] They may be able to regrow lost teeth.[4][5] Theyve restored the brains of patients that suffered strokes, months after the stroke happened[6]. But there are risks people have actually lost their vision, and using stem cells that arent from your body can cause weird things to happen in rare instances. Like teeth growing somewhere in your body where they dont belong. Eeewww.

Even if you dont have any medical issues, stem cell therapy offers a lot. It curbs aging by keeping your skin collagen and elastin-rich. It makes your joints stronger and more pliable. It can even increase (ahem) length and girth.

For the first time, stem cell therapy is becoming legally available to the general public, although its in a gray zone. Ive had a full-body treatment done. Actually, several. And I injected them into my brain three times and plan to do it twice a year until Im at least 180. Stem cell therapy is one of the biggest things Ive found that really moves the needle when it comes to anti-aging. (Pun intended.)

Here are my thoughts, along with what you need to know about stem cell therapy.

Stem cells are the play dough of the human body. Theyre ready to be shaped into any kind of tissue the body needs. Depending on the type you use, stem cells can turn into muscles, bones, joints, and even brain cells. Or yes, boy parts. Or girl parts, if youre so equipped. (My wife Dr. Lana did that procedure, and the results are amazing!)

Stem cells in their own are helpful, but they work better when you pair them with growth factors to guide them in the body. Growth factors are like guard rails: they keep the stem cells on the road until they reach their destination.

Stem cell therapy involves pulling stem cells from one part of your body, mixing them with growth factor from your blood, bone marrow, or other sources, and injecting them into another part.

If going to a doctor isnt in your budget, you can stimulate stem cells and growth factors on your own with a few lifestyle hacks. In fact, most of the practices in The Bulletproof Diet and Head Strong improve stem cells, in part because mitochondria(the power plants of your cells and the main topic in my books) heavily influence your stem cells.

More on that in a moment. First, lets talk about how to use stem cells.

When I did my stem cell therapy, I used mesenchymal stem cells. Theyre in every joint in your body, working to keep your connective tissue strong.

Over time, normal wear and tear can break down your joints, especially if you put them under a lot of stress. Mesenchymal stem cells release proteins that curb inflammation, keeping your joints strong. They also signal for repair, bringing in nutrients that fix damage. Stem cells can also turn into the type of tissue your body needs, replacing tissue entirely.

As you age, stem cell production drops. Your body often cant keep up with repair, especially if you injure yourself. Im doing fine, but I wanted to boost my stem cells before any real problems came up. I worked with Dr. Harry Adelson (hear him on Bulletproof Radio here) to get treatments all over.

When you get your stem cells extracted, it requires either liposuction for fat stem cells, or bone marrow, or both. But those are painful procedures so some doctors will allow you to send your stem cells to a facility that amplifies the stem cells and stores them for later use. Do this if you can afford it. This is a legal gray zone (the FDA says that if they are amplified theyre a drug, yet many physicians will offer it outside the U.S.) The reason you want to do this is that if you are ever injured, say with a traumatic brain injuryor any major trauma your stem cells could save your life. The younger you are when you get your stem cells banked, the better off you are, because stem cells are more effective when youre younger.

I was fortunate to be able to get my stem cells legally banked, so I have them available for regular use!

If youre looking into stem cell therapy, youll likely find doctors in two camps. Doctors extract stem cells from either bone marrow or fat.

I worked with Dr. Harry Adelson at Docere Medical because hes a pioneer. He uses both kinds of stem cells bone marrow and fat because he finds patients get the best of both worlds: the consistency of bone marrow-derived cells and the more impressive healing of fat-derived cells. Ive also worked with Kristen Comella and Dr. Robyn Benson, both of whom Id recommend.

If you dont want to go all-in with stem cell therapy, here are a few other ways to activate your stem cells.

Want a more in-depth look at stem cells from some of the worlds experts? Check out these episodes of Bulletproof Radio:

Thanks for reading and have a great week!

Sign-up for the Bulletproof mailing list and receive the latest news and updates!

Here is the original post:
How Adult Stem Cells Can Help Stop Pain and Reverse Aging

Adult Stem Cells in Greenville, SC

Adult Stem Cells | Posted by admin
Sep 23 2017

Stem cells are one of the most important advancements in modern medical science. Their potential applications for healing, aesthetic procedures and pain relief are nearly limitless. But many people are concerned about their creation: Is it true they all come from human embryos? The answer is no. Adult stem cells are created entirely from adult tissue; no embryos are used in the process. These stem cells can be drawn from either the patient or from a donor bank.

Request more information about adult stem cells today: Call (843) 492-4884 or contact Dr. Dalal Akoury online.

Adult stem cells are stem cells drawn from the body of a healthy adult rather than from embryonic tissue. This means they aren’t controversial like embryonic stem cells, which may require the destruction of a human embryo.

Adult stem cells, like all stem cells, have special regenerative properties. This is because they take on the properties of the surrounding cells. Because of this, adult stem cells have many different uses, from minor aesthetic treatments to potentially life-saving procedures.

Adult stem cells come either from the patient himself or from a donor bank. It is much more common for the stem cells to be drawn from the patient. When the stem cells are drawn from the patient, they are also called autologous stem cells.

Adult stem cells can be used in a variety of medical treatments. The list below represents a small portion of the many possible adult stem cell treatments. As medical science and the understanding of stem cells advance, the number of treatments will likely increase as well.

Possible treatmentsinclude:

Adult stem cells are generally placed into two categories, which are differentiated by how they are derived from the body. The categories are adipose stem cells and bone marrow stem cells.

Adult stem cells are often combined with platelet-rich plasma (PRP), but not always. Platelet-rich plasma is taken from the patient’s blood and is believed to enhance the regenerative qualities of stem cells because it has regenerative qualities as well.

Adult stem cellsare thought to have the healing and regeneration power of embryonic stem cells, but without the controversy or potential moral issues. Request more information about adult stem cells today: Call (843) 492-4884 or contact Dr. Dalal Akoury online.

Read the original here:
Adult Stem Cells in Greenville, SC

4. The Adult Stem Cell | stemcells.nih.gov

Adult Stem Cells | Posted by admin
Sep 19 2017

For many years, researchers have been seeking to understand the body’s ability to repair and replace the cells and tissues of some organs, but not others. After years of work pursuing the how and why of seemingly indiscriminant cell repair mechanisms, scientists have now focused their attention on adult stem cells. It has long been known that stem cells are capable of renewing themselves and that they can generate multiple cell types. Today, there is new evidence that stem cells are present in far more tissues and organs than once thought and that these cells are capable of developing into more kinds of cells than previously imagined. Efforts are now underway to harness stem cells and to take advantage of this new found capability, with the goal of devising new and more effective treatments for a host of diseases and disabilities. What lies ahead for the use of adult stem cells is unknown, but it is certain that there are many research questions to be answered and that these answers hold great promise for the future.

Adult stem cells, like all stem cells, share at least two characteristics. First, they can make identical copies of themselves for long periods of time; this ability to proliferate is referred to as long-term self-renewal. Second, they can give rise to mature cell types that have characteristic morphologies (shapes) and specialized functions. Typically, stem cells generate an intermediate cell type or types before they achieve their fully differentiated state. The intermediate cell is called a precursor or progenitor cell. Progenitor or precursor cells in fetal or adult tissues are partly differentiated cells that divide and give rise to differentiated cells. Such cells are usually regarded as “committed” to differentiating along a particular cellular development pathway, although this characteristic may not be as definitive as once thought [82] (see Figure 4.1. Distinguishing Features of Progenitor/Precursor Cells and Stem Cells).

Figure 4.1. Distinguishing Features of Progenitor/Precursor Cells and Stem Cells. A stem cell is an unspecialized cell that is capable of replicating or self renewing itself and developing into specialized cells of a variety of cell types. The product of a stem cell undergoing division is at least one additional stem cell that has the same capabilities of the originating cell. Shown here is an example of a hematopoietic stem cell producing a second generation stem cell and a neuron. A progenitor cell (also known as a precursor cell) is unspecialized or has partial characteristics of a specialized cell that is capable of undergoing cell division and yielding two specialized cells. Shown here is an example of a myeloid progenitor/precursor undergoing cell division to yield two specialized cells (a neutrophil and a red blood cell).

( 2001 Terese Winslow, Lydia Kibiuk)

Adult stem cells are rare. Their primary functions are to maintain the steady state functioning of a cellcalled homeostasisand, with limitations, to replace cells that die because of injury or disease [44, 58]. For example, only an estimated 1 in 10,000 to 15,000 cells in the bone marrow is a hematopoietic (bloodforming) stem cell (HSC) [105]. Furthermore, adult stem cells are dispersed in tissues throughout the mature animal and behave very differently, depending on their local environment. For example, HSCs are constantly being generated in the bone marrow where they differentiate into mature types of blood cells. Indeed, the primary role of HSCs is to replace blood cells [26] (see Chapter 5. Hematopoietic Stem Cells). In contrast, stem cells in the small intestine are stationary, and are physically separated from the mature cell types they generate. Gut epithelial stem cells (or precursors) occur at the bases of cryptsdeep invaginations between the mature, differentiated epithelial cells that line the lumen of the intestine. These epithelial crypt cells divide fairly often, but remain part of the stationary group of cells they generate [93].

Unlike embryonic stem cells, which are defined by their origin (the inner cell mass of the blastocyst), adult stem cells share no such definitive means of characterization. In fact, no one knows the origin of adult stem cells in any mature tissue. Some have proposed that stem cells are somehow set aside during fetal development and restrained from differentiating. Definitions of adult stem cells vary in the scientific literature range from a simple description of the cells to a rigorous set of experimental criteria that must be met before characterizing a particular cell as an adult stem cell. Most of the information about adult stem cells comes from studies of mice. The list of adult tissues reported to contain stem cells is growing and includes bone marrow, peripheral blood, brain, spinal cord, dental pulp, blood vessels, skeletal muscle, epithelia of the skin and digestive system, cornea, retina, liver, and pancreas.

In order to be classified as an adult stem cell, the cell should be capable of self-renewal for the lifetime of the organism. This criterion, although fundamental to the nature of a stem cell, is difficult to prove in vivo. It is nearly impossible, in an organism as complex as a human, to design an experiment that will allow the fate of candidate adult stem cells to be identified in vivo and tracked over an individual’s entire lifetime.

Ideally, adult stem cells should also be clonogenic. In other words, a single adult stem cell should be able to generate a line of genetically identical cells, which then gives rise to all the appropriate, differentiated cell types of the tissue in which it resides. Again, this property is difficult to demonstrate in vivo; in practice, scientists show either that a stem cell is clonogenic in vitro, or that a purified population of candidate stem cells can repopulate the tissue.

An adult stem cell should also be able to give rise to fully differentiated cells that have mature phenotypes, are fully integrated into the tissue, and are capable of specialized functions that are appropriate for the tissue. The term phenotype refers to all the observable characteristics of a cell (or organism); its shape (morphology); interactions with other cells and the non-cellular environment (also called the extracellular matrix); proteins that appear on the cell surface (surface markers); and the cell’s behavior (e.g., secretion, contraction, synaptic transmission).

The majority of researchers who lay claim to having identified adult stem cells rely on two of these characteristicsappropriate cell morphology, and the demonstration that the resulting, differentiated cell types display surface markers that identify them as belonging to the tissue. Some studies demonstrate that the differentiated cells that are derived from adult stem cells are truly functional, and a few studies show that cells are integrated into the differentiated tissue in vivo and that they interact appropriately with neighboring cells. At present, there is, however, a paucity of research, with a few notable exceptions, in which researchers were able to conduct studies of genetically identical (clonal) stem cells. In order to fully characterize the regenerating and self-renewal capabilities of the adult stem cell, and therefore to truly harness its potential, it will be important to demonstrate that a single adult stem cell can, indeed, generate a line of genetically identical cells, which then gives rise to all the appropriate, differentiated cell types of the tissue in which it resides.

Adult stem cells have been identified in many animal and human tissues. In general, three methods are used to determine whether candidate adult stem cells give rise to specialized cells. Adult stem cells can be labeled in vivo and then they can be tracked. Candidate adult stem cells can also be isolated and labeled and then transplanted back into the organism to determine what becomes of them. Finally, candidate adult stem cells can be isolated, grown in vitro and manipulated, by adding growth factors or introducing genes that help determine what differentiated cells types they will yield. For example, currently, scientists believe that stem cells in the fetal and adult brain divide and give rise to more stem cells or to several types of precursor cells, which give rise to nerve cells (neurons), of which there are many types.

It is often difficultif not impossibleto distinguish adult, tissue-specific stem cells from progenitor cells, which are found in fetal or adult tissues and are partly differentiated cells that divide and give rise to differentiated cells. These are cells found in many organs that are generally thought to be present to replace cells and maintain the integrity of the tissue. Progenitor cells give rise to certain types of cellssuch as the blood cells known as T lymphocytes, B lymphocytes, and natural killer cellsbut are not thought to be capable of developing into all the cell types of a tissue and as such are not truly stem cells. The current wave of excitement over the existence of stem cells in many adult tissues is perhaps fueling claims that progenitor or precursor cells in those tissues are instead stem cells. Thus, there are reports of endothelial progenitor cells, skeletal muscle stem cells, epithelial precursors in the skin and digestive system, as well as some reports of progenitors or stem cells in the pancreas and liver. A detailed summary of some of the evidence for the existence of stem cells in various tissues and organs is presented later in the chapter.

It was not until recently that anyone seriously considered the possibility that stem cells in adult tissues could generate the specialized cell types of another type of tissue from which they normally resideeither a tissue derived from the same embryonic germ layer or from a different germ layer (see Table 1.1. Embryonic Germ Layers From Which Differentiated Tissues Develop). For example, studies have shown that blood stem cells (derived from mesoderm) may be able to generate both skeletal muscle (also derived from mesoderm) and neurons (derived from ectoderm). That realization has been triggered by a flurry of papers reporting that stem cells derived from one adult tissue can change their appearance and assume characteristics that resemble those of differentiated cells from other tissues.

The term plasticity, as used in this report, means that a stem cell from one adult tissue can generate the differentiated cell types of another tissue. At this time, there is no formally accepted name for this phenomenon in the scientific literature. It is variously referred to as “plasticity” [15, 52], “unorthodox differentiation” [10] or “transdifferentiation” [7, 54].

To be able to claim that adult stem cells demonstrate plasticity, it is first important to show that a cell population exists in the starting tissue that has the identifying features of stem cells. Then, it is necessary to show that the adult stem cells give rise to cell types that normally occur in a different tissue. Neither of these criteria is easily met. Simply proving the existence of an adult stem cell population in a differentiated tissue is a laborious process. It requires that the candidate stem cells are shown to be self-renewing, and that they can give rise to the differentiated cell types that are characteristic of that tissue.

To show that the adult stem cells can generate other cell types requires them to be tracked in their new environment, whether it is in vitro or in vivo. In general, this has been accomplished by obtaining the stem cells from a mouse that has been genetically engineered to express a molecular tag in all its cells. It is then necessary to show that the labeled adult stem cells have adopted key structural and biochemical characteristics of the new tissue they are claimed to have generated. Ultimatelyand most importantlyit is necessary to demonstrate that the cells can integrate into their new tissue environment, survive in the tissue, and function like the mature cells of the tissue.

In the experiments reported to date, adult stem cells may assume the characteristics of cells that have developed from the same primary germ layer or a different germ layer (see Figure 4.2. Preliminary Evidence of Plasticity Among Nonhuman Adult Stem Cells). For example, many plasticity experiments involve stem cells derived from bone marrow, which is a mesodermal derivative. The bone marrow stem cells may then differentiate into another mesodermally derived tissue such as skeletal muscle [28, 43], cardiac muscle [51, 71] or liver [4, 54, 97].

Figure 4.2. Preliminary Evidence of Plasticity Among Nonhuman Adult Stem Cells.

( 2001 Terese Winslow, Lydia Kibiuk, Caitlin Duckwall)

Alternatively, adult stem cells may differentiate into a tissue thatduring normal embryonic developmentwould arise from a different germ layer. For example, bone marrow-derived cells may differentiate into neural tissue, which is derived from embryonic ectoderm [15, 65]. Andreciprocallyneural stem cell lines cultured from adult brain tissue may differentiate to form hematopoietic cells [13], or even give rise to many different cell types in a chimeric embryo [17]. In both cases cited above, the cells would be deemed to show plasticity, but in the case of bone marrow stem cells generating brain cells, the finding is less predictable.

In order to study plasticity within and across germ layer lines, the researcher must be sure that he/she is using only one kind of adult stem cell. The vast majority of experiments on plasticity have been conducted with adult stem cells derived either from the bone marrow or the brain. The bone marrow-derived cells are sometimes sortedusing a panel of surface markersinto populations of hematopoietic stem cells or bone marrow stromal cells [46, 54, 71]. The HSCs may be highly purified or partially purified, depending on the conditions used. Another way to separate population of bone marrow cells is by fractionation to yield cells that adhere to a growth substrate (stromal cells) or do not adhere (hematopoietic cells) [28].

To study plasticity of stem cells derived from the brain, the researcher must overcome several problems. Stem cells from the central nervous system (CNS), unlike bone marrow cells, do not occur in a single, accessible location. Instead, they are scattered in three places, at least in rodent brainthe tissue around the lateral ventricles in the forebrain, a migratory pathway for the cells that leads from the ventricles to the olfactory bulbs, and the hippocampus. Many of the experiments with CNS stem cells involve the formation of neurospheres, round aggregates of cells that are sometimes clonally derived. But it is not possible to observe cells in the center of a neurosphere, so to study plasticity in vitro, the cells are usually dissociated and plated in monolayers. To study plasticity in vivo, the cells may be dissociated before injection into the circulatory system of the recipient animal [13], or injected as neurospheres [17].

The differentiated cell types that result from plasticity are usually reported to have the morphological characteristics of the differentiated cells and to display their characteristic surface markers. In reports that transplanted adult stem cells show plasticity in vivo, the stem cells typically are shown to have integrated into a mature host tissue and assumed at least some of its characteristics [15, 28, 51, 65, 71]. Many plasticity experiments involve injury to a particular tissue, which is intended to model a particular human disease or injury [13, 54, 71]. However, there is limited evidence to date that such adult stem cells can generate mature, fully functional cells or that the cells have restored lost function in vivo [54]. Most of the studies that show the plasticity of adult stem cells involve cells that are derived from the bone marrow [15, 28, 54, 65, 77] or brain [13, 17]. To date, adult stem cells are best characterized in these two tissues, which may account for the greater number of plasticity studies based on bone marrow and brain. Collectively, studies on plasticity suggest that stem cell populations in adult mammals are not fixed entities, and that after exposure to a new environment, they may be able to populate other tissues and possibly differentiate into other cell types.

It is not yet possible to say whether plasticity occurs normally in vivo. Some scientists think it may [14, 64], but as yet there is no evidence to prove it. Also, it is not yet clear to what extent plasticity can occur in experimental settings, and howor whetherthe phenomenon can be harnessed to generate tissues that may be useful for therapeutic transplantation. If the phenomenon of plasticity is to be used as a basis for generating tissue for transplantation, the techniques for doing it will need to be reproducible and reliable (see Chapter 10. Assessing Human Stem Cell Safety). In some cases, debate continues about observations that adult stem cells yield cells of tissue types different than those from which they were obtained [7, 68].

More than 30 years ago, Altman and Das showed that two regions of the postnatal rat brain, the hippocampus and the olfactory bulb, contain dividing cells that become neurons [5, 6]. Despite these reports, the prevailing view at the time was that nerve cells in the adult brain do not divide. In fact, the notion that stem cells in the adult brain can generate its three major cell typesastrocytes and oligodendrocytes, as well as neuronswas not accepted until far more recently. Within the past five years, a series of studies has shown that stem cells occur in the adult mammalian brain and that these cells can generate its three major cell lineages [35, 48, 63, 66, 90, 96, 104] (see Chapter 8. Rebuilding the Nervous System with Stem Cells).

Today, scientists believe that stem cells in the fetal and adult brain divide and give rise to more stem cells or to several types of precursor cells. Neuronal precursors (also called neuroblasts) divide and give rise to nerve cells (neurons), of which there are many types. Glial precursors give rise to astrocytes or oligodendrocytes. Astrocytes are a kind of glial cell, which lend both mechanical and metabolic support for neurons; they make up 70 to 80 percent of the cells of the adult brain. Oligodendrocytes make myelin, the fatty material that ensheathes nerve cell axons and speeds nerve transmission. Under normal, in vivo conditions, neuronal precursors do not give rise to glial cells, and glial precursors do not give rise to neurons. In contrast, a fetal or adult CNS (central nervous systemthe brain and spinal cord) stem cell may give rise to neurons, astrocytes, or oligodendrocytes, depending on the signals it receives and its three-dimensional environment within the brain tissue. There is now widespread consensus that the adult mammalian brain does contain stem cells. However, there is no consensus about how many populations of CNS stem cells exist, how they may be related, and how they function in vivo. Because there are no markers currently available to identify the cells in vivo, the only method for testing whether a given population of CNS cells contains stem cells is to isolate the cells and manipulate them in vitro, a process that may change their intrinsic properties [67].

Despite these barriers, three groups of CNS stem cells have been reported to date. All occur in the adult rodent brain and preliminary evidence indicates they also occur in the adult human brain. One group occupies the brain tissue next to the ventricles, regions known as the ventricular zone and the sub-ventricular zone (see discussion below). The ventricles are spaces in the brain filled with cerebrospinal fluid. During fetal development, the tissue adjacent to the ventricles is a prominent region of actively dividing cells. By adulthood, however, this tissue is much smaller, although it still appears to contain stem cells [70].

A second group of adult CNS stem cells, described in mice but not in humans, occurs in a streak of tissue that connects the lateral ventricle and the olfactory bulb, which receives odor signals from the nose. In rodents, olfactory bulb neurons are constantly being replenished via this pathway [59, 61]. A third possible location for stem cells in adult mouse and human brain occurs in the hippocampus, a part of the brain thought to play a role in the formation of certain kinds of memory [27, 34].

Central Nervous System Stem Cells in the Subventricular Zone. CNS stem cells found in the forebrain that surrounds the lateral ventricles are heterogeneous and can be distinguished morphologically. Ependymal cells, which are ciliated, line the ventricles. Adjacent to the ependymal cell layer, in a region sometimes designated as the subependymal or subventricular zone, is a mixed cell population that consists of neuroblasts (immature neurons) that migrate to the olfactory bulb, precursor cells, and astrocytes. Some of the cells divide rapidly, while others divide slowly. The astrocyte-like cells can be identified because they contain glial fibrillary acidic protein (GFAP), whereas the ependymal cells stain positive for nestin, which is regarded as a marker of neural stem cells. Which of these cells best qualifies as a CNS stem cell is a matter of debate [76].

A recent report indicates that the astrocytes that occur in the subventricular zone of the rodent brain act as neural stem cells. The cells with astrocyte markers appear to generate neurons in vivo, as identified by their expression of specific neuronal markers. The in vitro assay to demonstrate that these astrocytes are, in fact, stem cells involves their ability to form neurospheresgroupings of undifferentiated cells that can be dissociated and coaxed to differentiate into neurons or glial cells [25]. Traditionally, these astrocytes have been regarded as differentiated cells, not as stem cells and so their designation as stem cells is not universally accepted.

A series of similar in vitro studies based on the formation of neurospheres was used to identify the subependymal zone as a source of adult rodent CNS stem cells. In these experiments, single, candidate stem cells derived from the subependymal zone are induced to give rise to neurospheres in the presence of mitogenseither epidermal growth factor (EGF) or fibroblast growth factor-2 (FGF-2). The neurospheres are dissociated and passaged. As long as a mitogen is present in the culture medium, the cells continue forming neurospheres without differentiating. Some populations of CNS cells are more responsive to EGF, others to FGF [100]. To induce differentiation into neurons or glia, cells are dissociated from the neurospheres and grown on an adherent surface in serum-free medium that contains specific growth factors. Collectively, the studies demonstrate that a population of cells derived from the adult rodent brain can self-renew and differentiate to yield the three major cell types of the CNS cells [41, 69, 74, 102].

Central Nervous System Stem Cells in the Ventricular Zone. Another group of potential CNS stem cells in the adult rodent brain may consist of the ependymal cells themselves [47]. Ependymal cells, which are ciliated, line the lateral ventricles. They have been described as non-dividing cells [24] that function as part of the blood-brain barrier [22]. The suggestion that ependymal cells from the ventricular zone of the adult rodent CNS may be stem cells is therefore unexpected. However, in a recent study, in which two molecular tagsthe fluorescent marker Dil, and an adenovirus vector carrying lacZ tagswere used to label the ependymal cells that line the entire CNS ventricular system of adult rats, it was shown that these cells could, indeed, act as stem cells. A few days after labeling, fluorescent or lacZ+ cells were observed in the rostral migratory stream (which leads from the lateral ventricle to the olfactory bulb), and then in the olfactory bulb itself. The labeled cells in the olfactory bulb also stained for the neuronal markers III tubulin and Map2, which indicated that ependymal cells from the ventricular zone of the adult rat brain had migrated along the rostral migratory stream to generate olfactory bulb neurons in vivo [47].

To show that Dil+ cells were neural stem cells and could generate astrocytes and oligodendrocytes as well as neurons, a neurosphere assay was performed in vitro. Dil-labeled cells were dissociated from the ventricular system and cultured in the presence of mitogen to generate neurospheres. Most of the neurospheres were Dil+; they could self-renew and generate neurons, astrocytes, and oligodendrocytes when induced to differentiate. Single, Dil+ ependymal cells isolated from the ventricular zone could also generate self-renewing neurospheres and differentiate into neurons and glia.

To show that ependymal cells can also divide in vivo, bromodeoxyuridine (BrdU) was administered in the drinking water to rats for a 2- to 6-week period. Bromodeoxyuridine (BrdU) is a DNA precursor that is only incorporated into dividing cells. Through a series of experiments, it was shown that ependymal cells divide slowly in vivo and give rise to a population of progenitor cells in the subventricular zone [47]. A different pattern of scattered BrdU-labeled cells was observed in the spinal cord, which suggested that ependymal cells along the central canal of the cord occasionally divide and give rise to nearby ependymal cells, but do not migrate away from the canal.

Collectively, the data suggest that CNS ependymal cells in adult rodents can function as stem cells. The cells can self-renew, and most proliferate via asymmetrical division. Many of the CNS ependymal cells are not actively dividing (quiescent), but they can be stimulated to do so in vitro (with mitogens) or in vivo (in response to injury). After injury, the ependymal cells in the spinal cord only give rise to astrocytes, not to neurons. How and whether ependymal cells from the ventricular zone are related to other candidate populations of CNS stem cells, such as those identified in the hippocampus [34], is not known.

Are ventricular and subventricular zone CNS stem cells the same population? These studies and other leave open the question of whether cells that directly line the ventriclesthose in the ventricular zoneor cells that are at least a layer removed from this zonein the subventricular zone are the same population of CNS stem cells. A new study, based on the finding that they express different genes, confirms earlier reports that the ventricular and subventricular zone cell populations are distinct. The new research utilizes a technique called representational difference analysis, together with cDNA microarray analysis, to monitor the patterns of gene expression in the complex tissue of the developing and postnatal mouse brain. The study revealed the expression of a panel of genes known to be important in CNS development, such as L3-PSP (which encodes a phosphoserine phosphatase important in cell signaling), cyclin D2 (a cell cycle gene), and ERCC-1 (which is important in DNA excision repair). All of these genes in the recent study were expressed in cultured neurospheres, as well as the ventricular zone, the subventricular zone, and a brain area outside those germinal zones. This analysis also revealed the expression of novel genes such as A16F10, which is similar to a gene in an embryonic cancer cell line. A16F10 was expressed in neurospheres and at high levels in the subventricular zone, but not significantly in the ventricular zone. Interestingly, several of the genes identified in cultured neurospheres were also expressed in hematopoietic cells, suggesting that neural stem cells and blood-forming cells may share aspects of their genetic programs or signaling systems [38]. This finding may help explain recent reports that CNS stem cells derived from mouse brain can give rise to hematopoietic cells after injection into irradiated mice [13].

Central Nervous System Stem Cells in the Hippocampus. The hippocampus is one of the oldest parts of the cerebral cortex, in evolutionary terms, and is thought to play an important role in certain forms of memory. The region of the hippocampus in which stem cells apparently exist in mouse and human brains is the subgranular zone of the dentate gyrus. In mice, when BrdU is used to label dividing cells in this region, about 50% of the labeled cells differentiate into cells that appear to be dentate gyrus granule neurons, and 15% become glial cells. The rest of the BrdU-labeled cells do not have a recognizable phenotype [90]. Interestingly, many, if not all the BrdU-labeled cells in the adult rodent hippocampus occur next to blood vessels [33].

In the human dentate gyrus, some BrdU-labeled cells express NeuN, neuron-specific enolase, or calbindin, all of which are neuronal markers. The labeled neuron-like cells resemble dentate gyrus granule cells, in terms of their morphology (as they did in mice). Other BrdU-labeled cells express glial fibrillary acidic protein (GFAP) an astrocyte marker. The study involved autopsy material, obtained with family consent, from five cancer patients who had been injected with BrdU dissolved in saline prior to their death for diagnostic purposes. The patients ranged in age from 57 to 72 years. The greatest number of BrdU-labeled cells were identified in the oldest patient, suggesting that new neuron formation in the hippocampus can continue late in life [27].

Fetal Central Nervous System Stem Cells. Not surprisingly, fetal stem cells are numerous in fetal tissues, where they are assumed to play an important role in the expansion and differentiation of all tissues of the developing organism. Depending on the developmental stage of an animal, fetal stem cells and precursor cellswhich arise from stem cellsmay make up the bulk of a tissue. This is certainly true in the brain [48], although it has not been demonstrated experimentally in many tissues.

It may seem obvious that the fetal brain contains stem cells that can generate all the types of neurons in the brain as well as astrocytes and oligodendrocytes, but it was not until fairly recently that the concept was proven experimentally. There has been a long-standing question as to whether or not the same cell type gives rise to both neurons and glia. In studies of the developing rodent brain, it has now been shown that all the major cell types in the fetal brain arise from a common population of progenitor cells [20, 34, 48, 80, 108].

Neural stem cells in the mammalian fetal brain are concentrated in seven major areas: olfactory bulb, ependymal (ventricular) zone of the lateral ventricles (which lie in the forebrain), subventricular zone (next to the ependymal zone), hippocampus, spinal cord, cerebellum (part of the hindbrain), and the cerebral cortex. Their number and pattern of development vary in different species. These cells appear to represent different stem cell populations, rather than a single population of stem cells that is dispersed in multiple sites. The normal development of the brain depends not only on the proliferation and differentiation of these fetal stem cells, but also on a genetically programmed process of selective cell death called apoptosis [76].

Little is known about stem cells in the human fetal brain. In one study, however, investigators derived clonal cell lines from CNS stem cells isolated from the diencephalon and cortex of human fetuses, 10.5 weeks post-conception [103]. The study is unusual, not only because it involves human CNS stem cells obtained from fetal tissue, but also because the cells were used to generate clonal cell lines of CNS stem cells that generated neurons, astrocytes, and oligodendrocytes, as determined on the basis of expressed markers. In a few experiments described as “preliminary,” the human CNS stem cells were injected into the brains of immunosuppressed rats where they apparently differentiated into neuron-like cells or glial cells.

In a 1999 study, a serum-free growth medium that included EGF and FGF2 was devised to grow the human fetal CNS stem cells. Although most of the cells died, occasionally, single CNS stem cells survived, divided, and ultimately formed neurospheres after one to two weeks in culture. The neurospheres could be dissociated and individual cells replated. The cells resumed proliferation and formed new neurospheres, thus establishing an in vitro system that (like the system established for mouse CNS neurospheres) could be maintained up to 2 years. Depending on the culture conditions, the cells in the neurospheres could be maintained in an undifferentiated dividing state (in the presence of mitogen), or dissociated and induced to differentiate (after the removal of mitogen and the addition of specific growth factors to the culture medium). The differentiated cells consisted mostly of astrocytes (75%), some neurons (13%) and rare oligodendrocytes (1.2%). The neurons generated under these conditions expressed markers indicating they were GABAergic, [the major type of inhibitory neuron in the mammalian CNS responsive to the amino acid neurotransmitter, gammaaminobutyric acid (GABA)]. However, catecholamine-like cells that express tyrosine hydroxylase (TH, a critical enzyme in the dopamine-synthesis pathway) could be generated, if the culture conditions were altered to include different medium conditioned by a rat glioma line (BB49). Thus, the report indicates that human CNS stem cells obtained from early fetuses can be maintained in vitro for a long time without differentiating, induced to differentiate into the three major lineages of the CNS (and possibly two kinds of neurons, GABAergic and TH-positive), and engraft (in rats) in vivo [103].

Central Nervous System Neural Crest Stem Cells. Neural crest cells differ markedly from fetal or adult neural stem cells. During fetal development, neural crest cells migrate from the sides of the neural tube as it closes. The cells differentiate into a range of tissues, not all of which are part of the nervous system [56, 57, 91]. Neural crest cells form the sympathetic and parasympathetic components of the peripheral nervous system (PNS), including the network of nerves that innervate the heart and the gut, all the sensory ganglia (groups of neurons that occur in pairs along the dorsal surface of the spinal cord), and Schwann cells, which (like oligodendrocytes in the CNS) make myelin in the PNS. The non-neural tissues that arise from the neural crest are diverse. They populate certain hormone-secreting glandsincluding the adrenal medulla and Type I cells in the carotid bodypigment cells of the skin (melanocytes), cartilage and bone in the face and skull, and connective tissue in many parts of the body [76].

Thus, neural crest cells migrate far more extensively than other fetal neural stem cells during development, form mesenchymal tissues, most of which develop from embryonic mesoderm as well as the components of the CNS and PNS which arises from embryonic ectoderm. This close link, in neural crest development, between ectodermally derived tissues and mesodermally derived tissues accounts in part for the interest in neural crest cells as a kind of stem cell. In fact, neural crest cells meet several criteria of stem cells. They can self-renew (at least in the fetus) and can differentiate into multiple cells types, which include cells derived from two of the three embryonic germ layers [76].

Recent studies indicate that neural crest cells persist late into gestation and can be isolated from E14.5 rat sciatic nerve, a peripheral nerve in the hindlimb. The cells incorporate BrdU, indicating that they are dividing in vivo. When transplanted into chick embryos, the rat neural crest cells develop into neurons and glia, an indication of their stem cell-like properties [67]. However, the ability of rat E14.5 neural crest cells taken from sciatic nerve to generate nerve and glial cells in chick is more limited than neural crest cells derived from younger, E10.5 rat embryos. At the earlier stage of development, the neural tube has formed, but neural crest cells have not yet migrated to their final destinations. Neural crest cells from early developmental stages are more sensitive to bone morphogenetic protein 2 (BMP2) signaling, which may help explain their greater differentiation potential [106].

The notion that the bone marrow contains stem cells is not new. One population of bone marrow cells, the hematopoietic stem cells (HSCs), is responsible for forming all of the types of blood cells in the body. HSCs were recognized as a stem cells more than 40 years ago [9, 99]. Bone marrow stromal cellsa mixed cell population that generates bone, cartilage, fat, fibrous connective tissue, and the reticular network that supports blood cell formationwere described shortly after the discovery of HSCs [30, 32, 73]. The mesenchymal stem cells of the bone marrow also give rise to these tissues, and may constitute the same population of cells as the bone marrow stromal cells [78]. Recently, a population of progenitor cells that differentiates into endothelial cells, a type of cell that lines the blood vessels, was isolated from circulating blood [8] and identified as originating in bone marrow [89]. Whether these endothelial progenitor cells, which resemble the angioblasts that give rise to blood vessels during embryonic development, represent a bona fide population of adult bone marrow stem cells remains uncertain. Thus, the bone marrow appears to contain three stem cell populationshematopoietic stem cells, stromal cells, and (possibly) endothelial progenitor cells (see Figure 4.3. Hematopoietic and Stromal Stem Cell Differentiation).

Figure 4.3. Hematopoietic and Stromal Stem Cell Differentiation.

( 2001 Terese Winslow, Lydia Kibiuk)

Two more apparent stem cell types have been reported in circulating blood, but have not been shown to originate from the bone marrow. One population, called pericytes, may be closely related to bone marrow stromal cells, although their origin remains elusive [12]. The second population of blood-born stem cells, which occur in four species of animals testedguinea pigs, mice, rabbits, and humansresemble stromal cells in that they can generate bone and fat [53].

Hematopoietic Stem Cells. Of all the cell types in the body, those that survive for the shortest period of time are blood cells and certain kinds of epithelial cells. For example, red blood cells (erythrocytes), which lack a nucleus, live for approximately 120 days in the bloodstream. The life of an animal literally depends on the ability of these and other blood cells to be replenished continuously. This replenishment process occurs largely in the bone marrow, where HSCs reside, divide, and differentiate into all the blood cell types. Both HSCs and differentiated blood cells cycle from the bone marrow to the blood and back again, under the influence of a barrage of secreted factors that regulate cell proliferation, differentiation, and migration (see Chapter 5. Hematopoietic Stem Cells).

HSCs can reconstitute the hematopoietic system of mice that have been subjected to lethal doses of radiation to destroy their own hematopoietic systems. This test, the rescue of lethally irradiated mice, has become a standard by which other candidate stem cells are measured because it shows, without question, that HSCs can regenerate an entire tissue systemin this case, the blood [9, 99]. HSCs were first proven to be blood-forming stem cells in a series of experiments in mice; similar blood-forming stem cells occur in humans. HSCs are defined by their ability to self-renew and to give rise to all the kinds of blood cells in the body. This means that a single HSC is capable of regenerating the entire hematopoietic system, although this has been demonstrated only a few times in mice [72].

Over the years, many combinations of surface markers have been used to identify, isolate, and purify HSCs derived from bone marrow and blood. Undifferentiated HSCs and hematopoietic progenitor cells express c-kit, CD34, and H-2K. These cells usually lack the lineage marker Lin, or express it at very low levels (Lin-/low). And for transplant purposes, cells that are CD34+ Thy1+ Lin- are most likely to contain stem cells and result in engraftment.

Two kinds of HSCs have been defined. Long-term HSCs proliferate for the lifetime of an animal. In young adult mice, an estimated 8 to 10 % of long-term HSCs enter the cell cycle and divide each day. Short-term HSCs proliferate for a limited time, possibly a few months. Long-term HSCs have high levels of telomerase activity. Telomerase is an enzyme that helps maintain the length of the ends of chromosomes, called telomeres, by adding on nucleotides. Active telomerase is a characteristic of undifferentiated, dividing cells and cancer cells. Differentiated, human somatic cells do not show telomerase activity. In adult humans, HSCs occur in the bone marrow, blood, liver, and spleen, but are extremely rare in any of these tissues. In mice, only 1 in 10,000 to 15,000 bone marrow cells is a long-term HSC [105].

Short-term HSCs differentiate into lymphoid and myeloid precursors, the two classes of precursors for the two major lineages of blood cells. Lymphoid precursors differentiate into T cells, B cells, and natural killer cells. The mechanisms and pathways that lead to their differentiation are still being investigated [1, 2]. Myeloid precursors differentiate into monocytes and macrophages, neutrophils, eosinophils, basophils, megakaryocytes, and erythrocytes [3]. In vivo, bone marrow HSCs differentiate into mature, specialized blood cells that cycle constantly from the bone marrow to the blood, and back to the bone marrow [26]. A recent study showed that short-term HSCs are a heterogeneous population that differ significantly in terms of their ability to self-renew and repopulate the hematopoietic system [42].

Attempts to induce HSC to proliferate in vitroon many substrates, including those intended to mimic conditions in the stromahave frustrated scientists for many years. Although HSCs proliferate readily in vivo, they usually differentiate or die in vitro [26]. Thus, much of the research on HSCs has been focused on understanding the factors, cell-cell interactions, and cell-matrix interactions that control their proliferation and differentiation in vivo, with the hope that similar conditions could be replicated in vitro. Many of the soluble factors that regulate HSC differentiation in vivo are cytokines, which are made by different cell types and are then concentrated in the bone marrow by the extracellular matrix of stromal cellsthe sites of blood formation [45, 107]. Two of the most-studied cytokines are granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) [40, 81].

Also important to HSC proliferation and differentiation are interactions of the cells with adhesion molecules in the extracellular matrix of the bone marrow stroma [83, 101, 110].

Bone Marrow Stromal Cells. Bone marrow (BM) stromal cells have long been recognized for playing an important role in the differentiation of mature blood cells from HSCs (see Figure 4.3. Hematopoietic and Stromal Stem Cell Differentiation). But stromal cells also have other important functions [30, 31]. In addition to providing the physical environment in which HSCs differentiate, BM stromal cells generate cartilage, bone, and fat. Whether stromal cells are best classified as stem cells or progenitor cells for these tissues is still in question. There is also a question as to whether BM stromal cells and so-called mesenchymal stem cells are the same population [78].

BM stromal cells have many features that distinguish them from HSCs. The two cell types are easy to separate in vitro. When bone marrow is dissociated, and the mixture of cells it contains is plated at low density, the stromal cells adhere to the surface of the culture dish, and the HSCs do not. Given specific in vitro conditions, BM stromal cells form colonies from a single cell called the colony forming unit-F (CFU-F). These colonies may then differentiate as adipocytes or myelosupportive stroma, a clonal assay that indicates the stem cell-like nature of stromal cells. Unlike HSCs, which do not divide in vitro (or proliferate only to a limited extent), BM stromal cells can proliferate for up to 35 population doublings in vitro [16]. They grow rapidly under the influence of such mitogens as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and insulin-like growth factor-1 (IGF-1) [12].

To date, it has not been possible to isolate a population of pure stromal cells from bone marrow. Panels of markers used to identify the cells include receptors for certain cytokines (interleukin-1, 3, 4, 6, and 7) receptors for proteins in the extracellular matrix, (ICAM-1 and 2, VCAM-1, the alpha-1, 2, and 3 integrins, and the beta-1, 2, 3 and 4 integrins), etc. [64]. Despite the use of these markers and another stromal cell marker called Stro-1, the origin and specific identity of stromal cells have remained elusive. Like HSCs, BM stromal cells arise from embryonic mesoderm during development, although no specific precursor or stem cell for stromal cells has been isolated and identified. One theory about their origin is that a common kind of progenitor cellperhaps a primordial endothelial cell that lines embryonic blood vesselsgives rise to both HSCs and to mesodermal precursors. The latter may then differentiate into myogenic precursors (the satellite cells that are thought to function as stem cells in skeletal muscle), and the BM stromal cells [10].

In vivo, the differentiation of stromal cells into fat and bone is not straightforward. Bone marrow adipocytes and myelosupportive stromal cellsboth of which are derived from BM stromal cellsmay be regarded as interchangeable phenotypes [10, 11]. Adipocytes do not develop until postnatal life, as the bones enlarge and the marrow space increases to accommodate enhanced hematopoiesis. When the skeleton stops growing, and the mass of HSCs decreases in a normal, age-dependent fashion, BM stromal cells differentiate into adipocytes, which fill the extra space. New bone formation is obviously greater during skeletal growth, although bone “turns over” throughout life. Bone forming cells are osteoblasts, but their relationship to BM stromal cells is not clear. New trabecular bone, which is the inner region of bone next to the marrow, could logically develop from the action of BM stromal cells. But the outside surface of bone also turns over, as does bone next to the Haversian system (small canals that form concentric rings within bone). And neither of these surfaces is in contact with BM stromal cells [10, 11].

It is often difficultif not impossibleto distinguish adult, tissue-specific stem cells from progenitor cells. With that caveat in mind, the following summary identifies reports of stem cells in various adult tissues.

Endothelial Progenitor Cells. Endothelial cells line the inner surfaces of blood vessels throughout the body, and it has been difficult to identify specific endothelial stem cells in either the embryonic or the adult mammal. During embryonic development, just after gastrulation, a kind of cell called the hemangioblast, which is derived from mesoderm, is presumed to be the precursor of both the hematopoietic and endothelial cell lineages. The embryonic vasculature formed at this stage is transient and consists of blood islands in the yolk sac. But hemangioblasts, per se, have not been isolated from the embryo and their existence remains in question. The process of forming new blood vessels in the embryo is called vasculogenesis. In the adult, the process of forming blood vessels from pre-existing blood vessels is called angiogenesis [50].

Evidence that hemangioblasts do exist comes from studies of mouse embryonic stem cells that are directed to differentiate in vitro. These studies have shown that a precursor cell derived from mouse ES cells that express Flk-1 [the receptor for vascular endothelial growth factor (VEGF) in mice] can give rise to both blood cells and blood vessel cells [88, 109]. Both VEGF and fibroblast growth factor-2 (FGF-2) play critical roles in endothelial cell differentiation in vivo [79].

Several recent reports indicate that the bone marrow contains cells that can give rise to new blood vessels in tissues that are ischemic (damaged due to the deprivation of blood and oxygen) [8, 29, 49, 94]. But it is unclear from these studies what cell type(s) in the bone marrow induced angiogenesis. In a study which sought to address that question, researchers found that adult human bone marrow contains cells that resemble embryonic hemangioblasts, and may therefore be called endothelial stem cells.

In more recent experiments, human bone marrow-derived cells were injected into the tail veins of rats with induced cardiac ischemia. The human cells migrated to the rat heart where they generated new blood vessels in the infarcted muscle (a process akin to vasculogenesis), and also induced angiogenesis. The candidate endothelial stem cells are CD34+(a marker for HSCs), and they express the transcription factor GATA-2 [51]. A similar study using transgenic mice that express the gene for enhanced green fluorescent protein (which allows the cells to be tracked), showed that bone-marrow-derived cells could repopulate an area of infarcted heart muscle in mice, and generate not only blood vessels, but also cardiomyocytes that integrated into the host tissue [71] (see Chapter 9. Can Stem Cells Repair a Damaged Heart?).

And, in a series of experiments in adult mammals, progenitor endothelial cells were isolated from peripheral blood (of mice and humans) by using antibodies against CD34 and Flk-1, the receptor for VEGF. The cells were mononuclear blood cells (meaning they have a nucleus) and are referred to as MBCD34+ cells and MBFlk1+ cells. When plated in tissue-culture dishes, the cells attached to the substrate, became spindle-shaped, and formed tube-like structures that resemble blood vessels. When transplanted into mice of the same species (autologous transplants) with induced ischemia in one limb, the MBCD34+ cells promoted the formation of new blood vessels [8]. Although the adult MBCD34+ and MBFlk1+ cells function in some ways like stem cells, they are usually regarded as progenitor cells.

Skeletal Muscle Stem Cells. Skeletal muscle, like the cardiac muscle of the heart and the smooth muscle in the walls of blood vessels, the digestive system, and the respiratory system, is derived from embryonic mesoderm. To date, at least three populations of skeletal muscle stem cells have been identified: satellite cells, cells in the wall of the dorsal aorta, and so-called “side population” cells.

Satellite cells in skeletal muscle were identified 40 years ago in frogs by electron microscopy [62], and thereafter in mammals [84]. Satellite cells occur on the surface of the basal lamina of a mature muscle cell, or myofiber. In adult mammals, satellite cells mediate muscle growth [85]. Although satellite cells are normally non-dividing, they can be triggered to proliferate as a result of injury, or weight-bearing exercise. Under either of these circumstances, muscle satellite cells give rise to myogenic precursor cells, which then differentiate into the myofibrils that typify skeletal muscle. A group of transcription factors called myogenic regulatory factors (MRFs) play important roles in these differentiation events. The so-called primary MRFs, MyoD and Myf5, help regulate myoblast formation during embryogenesis. The secondary MRFs, myogenin and MRF4, regulate the terminal differentiation of myofibrils [86].

With regard to satellite cells, scientists have been addressing two questions. Are skeletal muscle satellite cells true adult stem cells or are they instead precursor cells? Are satellite cells the only cell type that can regenerate skeletal muscle. For example, a recent report indicates that muscle stem cells may also occur in the dorsal aorta of mouse embryos, and constitute a cell type that gives rise both to muscle satellite cells and endothelial cells. Whether the dorsal aorta cells meet the criteria of a self-renewing muscle stem cell is a matter of debate [21].

Another report indicates that a different kind of stem cell, called an SP cell, can also regenerate skeletal muscle may be present in muscle and bone marrow. SP stands for a side population of cells that can be separated by fluorescence-activated cell sorting analysis. Intravenously injecting these muscle-derived stem cells restored the expression of dystrophin in mdx mice. Dystrophin is the protein that is defective in people with Duchenne’s muscular dystrophy; mdx mice provide a model for the human disease. Dystrophin expression in the SP cell-treated mice was lower than would be needed for clinical benefit. Injection of bone marrow- or muscle-derived SP cells into the dystrophic muscle of the mice yielded equivocal results that the transplanted cells had integrated into the host tissue. The authors conclude that a similar population of SP stem cells can be derived from either adult mouse bone marrow or skeletal muscle, and suggest “there may be some direct relationship between bone marrow-derived stem cells and other tissue- or organ-specific cells” [43]. Thus, stem cell or progenitor cell types from various mesodermally-derived tissues may be able to generate skeletal muscle.

Epithelial Cell Precursors in the Skin and Digestive System. Epithelial cells, which constitute 60 percent of the differentiated cells in the body are responsible for covering the internal and external surfaces of the body, including the lining of vessels and other cavities. The epithelial cells in skin and the digestive tract are replaced constantly. Other epithelial cell populationsin the ducts of the liver or pancreas, for exampleturn over more slowly. The cell population that renews the epithelium of the small intestine occurs in the intestinal crypts, deep invaginations in the lining of the gut. The crypt cells are often regarded as stem cells; one of them can give rise to an organized cluster of cells called a structural-proliferative unit [93].

The skin of mammals contains at least three populations of epithelial cells: epidermal cells, hair follicle cells, and glandular epithelial cells, such as those that make up the sweat glands. The replacement patterns for epithelial cells in these three compartments differ, and in all the compartments, a stem cell population has been postulated. For example, stem cells in the bulge region of the hair follicle appear to give rise to multiple cell types. Their progeny can migrate down to the base of the follicle where they become matrix cells, which may then give rise to different cell types in the hair follicle, of which there are seven [39]. The bulge stem cells of the follicle may also give rise to the epidermis of the skin [95].

Another population of stem cells in skin occurs in the basal layer of the epidermis. These stem cells proliferate in the basal region, and then differentiate as they move toward the outer surface of the skin. The keratinocytes in the outermost layer lack nuclei and act as a protective barrier. A dividing skin stem cell can divide asymmetrically to produce two kinds of daughter cells. One is another self-renewing stem cell. The second kind of daughter cell is an intermediate precursor cell which is then committed to replicate a few times before differentiating into keratinocytes. Self-renewing stem cells can be distinguished from this intermediate precusor cell by their higher level of 1 integrin expression, which signals keratinocytes to proliferate via a mitogen-activated protein (MAP) kinase [112]. Other signaling pathways include that triggered by -catenin, which helps maintain the stem-cell state [111], and the pathway regulated by the oncoprotein c-Myc, which triggers stem cells to give rise to transit amplifying cells [36].

Stem Cells in the Pancreas and Liver. The status of stem cells in the adult pancreas and liver is unclear. During embryonic development, both tissues arise from endoderm. A recent study indicates that a single precursor cell derived from embryonic endoderm may generate both the ventral pancreas and the liver [23]. In adult mammals, however, both the pancreas and the liver contain multiple kinds of differentiated cells that may be repopulated or regenerated by multiple types of stem cells. In the pancreas, endocrine (hormone-producing) cells occur in the islets of Langerhans. They include the beta cells (which produce insulin), the alpha cells (which secrete glucagon), and cells that release the peptide hormones somatostatin and pancreatic polypeptide. Stem cells in the adult pancreas are postulated to occur in the pancreatic ducts or in the islets themselves. Several recent reports indicate that stem cells that express nestinwhich is usually regarded as a marker of neural stem cellscan generate all of the cell types in the islets [60, 113] (see Chapter 7. Stem Cells and Diabetes).

The identity of stem cells that can repopulate the liver of adult mammals is also in question. Recent studies in rodents indicate that HSCs (derived from mesoderm) may be able to home to liver after it is damaged, and demonstrate plasticity in becoming into hepatocytes (usually derived from endoderm) [54, 77, 97]. But the question remains as to whether cells from the bone marrow normally generate hepatocytes in vivo. It is not known whether this kind of plasticity occurs without severe damage to the liver or whether HSCs from the bone marrow generate oval cells of the liver [18]. Although hepatic oval cells exist in the liver, it is not clear whether they actually generate new hepatocytes [87, 98]. Oval cells may arise from the portal tracts in liver and may give rise to either hepatocytes [19, 55] and to the epithelium of the bile ducts [37, 92]. Indeed, hepatocytes themselves, may be responsible for the well-know regenerative capacity of liver.

Chapter 3|Table of Contents|Chapter 5

Historical content: June 17, 2001

View original post here:
4. The Adult Stem Cell | stemcells.nih.gov

Clarkson professor awarded $420000 grant to study development of intestinal stem cells using zebrafish vertebrate … – North Country Now

Adult Stem Cells | Posted by admin
Sep 08 2017

Clarkson University Associate Professor of Biology Kenneth Wallace showcases his subjects of study — zebrafish — a common aquarium fish who share more than 70 percent of their genes with humans.

POTSDAM — Kenneth Wallace, associate professor of biology at Clarkson University, has been awarded a $420,000 grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development at the National Institutes of Health to investigate development of intestinal stem cells using the zebrafish vertebrate model system.

While much has been discovered about how stem cells are controlled during the adult phase, much less is known about the origins of these stem cell compartments. Little is known about when the stem cells form and how they are regulated. To uncover more about how stem cells are regulated during development of the intestine, Wallace will use zebrafish, which have become a widely-used vertebrate model system.

Zebrafish are a common aquarium fish, which are small easy to care for and have embryos that develop rapidly in an external environment. They also share more than 70 percent of their genes with humans, making them an excellent system to study both development and the origins of disease. Understanding of the genes and mechanisms involved in formation and regulation of the fish intestinal stem cells will provide information about how human intestinal stem cells are regulated.

Aside from the main research component, a secondary goal of the grant and project is to provide resources for undergraduate Clarkson University students to perform independent research on the molecular and cellular basis of embryonic development under Wallaces supervision. This will give them first-hand knowledge of developmental biology research practices and perhaps pique future interest in the field and research.

Read more here:
Clarkson professor awarded $420000 grant to study development of intestinal stem cells using zebrafish vertebrate … – North Country Now